Harnessing the Mesenchymal Stem Cell Secretome for the Treatment of Cardiovascular Disease
Name
Ranganath-2012-Harnessing the Mesen.pdf
Size
729.03 KB
Format
Adobe PDF
Checksum (MD5)
d3bc6ebe1a50e5a2401292fbca95b247
Author(s)
Ranganath, Sudhir H.
Levy, Oren
Inamdar, Maneesha S.
Karp, Jeffrey Michael
Ranganath, Sudhir H.
Date Issued
March 2012
Journal
Cell Stem Cell
Publisher
Elsevier B.V.
Citation
Ranganath, Sudhir H., Oren Levy, Maneesha S. Inamdar, and Jeffrey M. Karp. “Harnessing the Mesenchymal Stem Cell Secretome for the Treatment of Cardiovascular Disease.” Cell Stem Cell 10, no. 3 (March 2012): 244–258. © 2012 Elsevier B.V.
Version
Final published version
Abstract
The broad repertoire of secreted trophic and immunomodulatory cytokines produced by mesenchymal stem cells (MSCs), generally referred to as the MSC secretome, has considerable potential for the treatment of cardiovascular disease. However, harnessing this MSC secretome for meaningful therapeutic outcomes is challenging due to the limited control of cytokine production following their transplantation. This review outlines the current understanding of the MSC secretome as a therapeutic for treatment of ischemic heart disease. We discuss ongoing investigative directions aimed at improving cellular activity and characterizing the secretome and its regulation in greater detail. Finally, we provide insights on and perspectives for future development of the MSC secretome as a therapeutic tool.
MIT Department
Harvard University--MIT Division of Health Sciences and Technology
Terms of Use
Article is made available in accordance with the publisher's policy and may be subject to US copyright law. Please refer to the publisher's site for terms of use.
Persistent DSpace Link
DOI of Published Version
https://doi.org/10.1016/j.stem.2012.02.005
